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Abstract: Allergic rhinitis is a common disorder and involves the
reaction to environmental allergens with resultant nasal and eye
symptoms. The pathophysiologic mechanisms of the eye symptoms
in allergic conjunctivitis include a direct effect on the eye by
deposited allergen and indirect effects related to the deposition of
allergen in the nasal mucosa. One of these proposed mechanisms is
the existence of a nasal-ocular reflex whereby the nasal allergic
reaction leads to an afferent reflex response, the efferent limb of
which results in eye symptoms. Among the treatments available for
allergic rhinitis, intranasal steroids are most efficacious for nasal
symptoms and have also shown sizeable efficacy related to eye
symptoms. We speculated that the effect of intranasal steroids on
eye symptoms in allergic rhinitis was related to their inhibition of
the nasal-ocular reflex and present data previously generated from
our laboratory to support this assumption in a nasal challenge model.
Key Words: Nasal-ocular reflex, allergic rhinoconjuctivitis, nasal
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Allergic rhinitis is characterized by an IgE-mediated reac-tion to environmental allergens. It is a common disorder
affecting up to 40 million Americans with adult prevalence
estimates ranging from 10 to 30% and pediatric prevalence
estimates as high as 40% rendering it the most common
chronic condition in children.1 Several reports also support
substantial increases in the prevalence of allergic rhinocon-
junctivitis (AR) in developed countries in recent decades
making it an important health problem.1–3
Although often referred to as allergic rhinitis, this
disease actually involves eye symptoms in addition to the
nasal symptoms, hence the more appropriate term, AR. In
fact, recent epidemiologic data has shown that ocular symp-
toms, defined as ‘episodes of watery, itchy eyes,’ affected
40% of the adult population of the United States during a
12-month period.4 Another study showed that the incidence
of conjunctivitis was high (88%) in patients experiencing
allergic rhinitis during the cypress pollen season.5 Ocular
symptoms are not only common, but also distressing for
allergy sufferers, with more than 50% stating that watery and
red/itchy eyes were moderately to extremely bothersome in
the Allergies in America survey.6 Furthermore, in 15% of
sufferers, the ocular component of the allergic hypersensitiv-
ity reaction was the most bothersome symptom.6
In addition to the typical nasal and eye symptoms, AR
leads to a significant impairment of the quality of life of its
sufferers when measured by both generic and specific quality of
life instruments.7,8 Also associated with the disease are fatigue
and daytime sleepiness,7,9 reduced work productivity,10–12 im-
paired cognitive functioning,13,14 reduced learning abilities,15
and impaired sleep.16
The high prevalence of this benign, but chronic, con-
dition, its adverse effects on quality of life, work perfor-
mance, and productivity on the job, and the treatments sought
by the sufferers to alleviate the symptoms all result in
significant health care expenditure. The healthcare costs re-
lated to AR have been reported to be US$5.9 billion annually
in the United States, with medication use accounting for 25%
of these costs.17
PATHOPHYSIOLOGY OF AR
The pathophysiologic mechanisms involved in AR start
by the sensitization of the nasal mucosa to a certain allergen
that involves multiple interactions among antigen presenting
cells, T lymphocytes, and B cells and lead to the production
of antigen-specific IgE antibodies, which then localize to
mast cells and basophils. Subsequent exposure leads to cross-
linking of specific IgE receptors on mast cells and their
resultant degranulation, with the release of a host of inflam-
matory mediators that are, in large part, responsible for
allergic nasal symptoms that include sneezing, rhinorrhea,
itching, and nasal congestion. Other proinflammatory sub-
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stances are also generated after antigen exposure, most prom-
inent are eosinophil products and cytokines. Cytokines are
thought to be generated in part by lymphocytes, which are
abundant in resting and stimulated nasal mucosa, and also by
mast cells that have an important role in the storage and
production and secretion of cytokines. Cytokines will up-
regulate adhesion molecules on the vascular endothelium,
and possibly on marginating leukocytes, and lead to the
migration of these inflammatory cells into the site of tissue
inflammation. Various cytokines will also promote the che-
motaxis and survival of these recruited inflammatory cells
and lead to a secondary immune response by virtue of their
capability to promote IgE synthesis by B cells. Also important is
the nervous system, which amplifies the allergic reaction by
central and peripheral reflexes that result in changes at sites
distant from those of antigen deposition such as the eye, sinuses
and lower airway. These inflammatory changes lower the thresh-
old of mucosal responsiveness to various specific and nonspe-
cific stimuli, making allergic patients more responsive to stimuli
to which they are exposed every day.
The pathophysiologic mechanisms thought to be in-
volved in the generation of ocular symptoms in patients with
AR deserve special attention. It is likely that these symptoms
result both from the direct effects of allergen deposition on
the conjunctiva but also because of nasal ocular reflexes. In
support of direct allergen deposition resulting in the symp-
toms is the fact that ocular allergen challenge leads to
symptoms of watery and itchy eyes that are associated with
the release of inflammatory mediators, including histamine,
in ocular secretions.18,19 In support of nasal ocular reflexes is
the fact that nasonasal reflexes, that is, the generation of
symptoms in one nasal cavity in response to stimulation of
the other cavity, are well described and have been shown to
occur in response to several stimuli including allergen, his-
tamine, cold dry air, and capsaicin.20–24 There is also evi-
dence suggesting that nasal reflexes in response to allergen
challenge lead to an inflammatory response in the maxillary
sinus.25 Therefore, it seems plausible that allergen depositing
on the nasal mucosa can trigger afferent reflexes which then
propagate centrally. The efferent limbs of these reflexes could
then be propagated not only to the contralateral nasal cavity
but also to both conjunctivae and maxillary sinuses. Another
possible mechanism is that the nasal allergic reaction leads to
the release of mediators from the nose and up-regulation of
circulating cells, which, when attracted to the eye, are primed
to release more mediators and cause more severe symptoms.
One last possible mechanism of eye symptoms in AR is direct
propagation of allergen from the nose to the eye via the
nasolacrimal duct. This is not a likely mechanism as the
direction of flow of secretions within the nasolacrimal duct is
usually from the eye to the nose and not in the opposite
direction. Furthermore, the orifice of the nasolacrimal duct in
the nasal cavity is in the inferior meatus, well shielded by the
inferior turbinate from external penetration by allergen.
INTRANASAL STEROIDS
Many therapies are available for the treatment of AR.
These include antihistamines (systemic and topical), decon-
gestants (systemic and topical), leukotriene modifiers, anti-
cholinergics, intranasal steroids, and combination therapies.
Multiple studies comparing the different agents available for
treatment indeed support the superior efficacy of intranasal
steroids for allergic rhinitis.26,27 As a consequence, the com-
prehensive role of intranasal steroids is well recognized as
evidenced in both European and American guidelines for the
treatment of allergic rhinitis.28,29
Traditionally, allergic rhinitis clinical trials have fo-
cused on nasal symptoms; however, recent studies have
highlighted the prevalence and significance of ocular symp-
toms and thus, the effect of intranasal steroids on ocular
symptoms has been the focus of recent investigation. Indeed,
studies have shown that intranasal steroids are effective in the
control of ocular symptoms almost to the same degree that
they positively impact nasal symptoms. In an early placebo-
controlled, double blind, trial in subjects with seasonal aller-
gic rhinitis, Settipane and colleagues showed that both total
ocular and total nasal symptoms were significantly lowered
after treatment with triamcinolone acetonide.30 More re-
cently, ocular symptoms have been included in many trials
and more data has emerged to support the efficacy of intra-
nasal steroids in the control of eye symptoms in allergic
rhinitis.
In a retrospective analysis of pooled data from 7 ran-
domized, double-blind trials that compared the efficacy of
fluticasone propionate and placebo in seasonal allergic rhini-
tis in 1645 patients, intranasal fluticasone propionate was
found to be significantly more effective than placebo in
reducing the total ocular symptom scores after 1 and 2 weeks
of treatment.31 A similar post hoc analysis of the effect of
mometasone furoate on ocular symptoms was performed on
the results of a placebo controlled clinical trial performed in
353 subjects with seasonal allergic rhinitis.32 The subjects
recorded symptoms of ocular itching, tearing, and redness
and these were combined into a total ocular symptom score
(TOSS) for analysis. Mometasone furoate treatment resulted
in a significant reduction from baseline in TOSS compared
with placebo and the greatest improvement with individual
symptoms occurred with tearing. Fluticasone furoate, a more
recent addition to the intranasal steroid market in the United
States, is also more effective than placebo in reducing ocular
symptoms associated with seasonal allergic rhinitis. Com-
parison of once-daily intranasal fluticasone furoate with
placebo in subjects with seasonal allergic rhinitis who had
moderate-to-severe total ocular symptom scores at base-
line concluded that mean reductions from baseline were
significantly greater with fluticasone furoate than with
placebo for total ocular symptom scores and each of the
individual ocular symptoms.33 Two other published studies
support this conclusion.34,35
Although the mechanism of action of intranasal steroid
sprays in relieving ocular symptoms is not understood, sev-
eral mechanisms have been proposed. By decreasing nasal
inflammation, intranasal steroids may modulate or normalize
the excess stimulation of reflex neural activity that occurs
during allergic reactions, thereby reducing ocular symptoms.
In addition, by inhibiting local nasal inflammation, that is, the
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production of cytokines and infiltration of inflammatory cells,
intranasal steroids may have indirect systemic effects that
reduce the recruitment of inflammatory cells in other tissues,
including the eyes. This effect would be observed on the late
response to ocular challenge with antigen. Some authors have
suggested that intranasal steroids increase drainage in in-
flamed nasolacrimal ducts, thereby reducing conjunctival
exposure to allergens and inflammatory mediators. However,
duct patency has been found to be maintained in subjects who
had symptomatic allergic responses after ocular challenge.36
It has also been suggested that intranasal steroids might travel
through the nasolacrimal duct, exerting their anti-inflamma-
tory effect directly on the conjunctiva. However, the lack of
steroid-related side effects such as glaucoma and cata-
racts37,38 after prolonged use suggests that movement of
intranasal steroids through the nasolacrimal duct is not a
plausible mechanism for the ocular effects of these agents.
The Nasal-Ocular Reflex Mechanism of
Rhinoconjunctivitis and the Effect of Intranasal
Steroids on the Reflex
To attempt to explain the beneficial effect of intranasal
steroids on eye symptoms in AR, we focused on the nasal-
ocular reflex response. Prior studies of the nasal ocular reflex
after antigen stimulation have yielded mixed results. Lebel
and colleagues, in a nasal-challenge study, reported that
20% of allergic rhinitis sufferers experienced ocular symp-
toms during nasal provocation with grass pollen, suggesting
that allergic ocular symptoms can occur without direct expo-
sure of the conjunctiva to allergen.39 Loth and Bende, on the
other hand, concluded that nasal challenge with allergen does
not increase lacrimal gland secretion, because inhibition of
parasympathetic nerves by lidocaine did not reduce tears.40
The conclusions of their study can be questioned because the
placebo arm failed to demonstrate any significant increase in
lacrimation after nasal challenge with allergen thus putting
the value of the results obtained from the lidocaine arm of the
study in doubt. Other studies using different forms of stim-
ulation have supported the existence of a nasal-ocular reflex.
Zilstorff-Pedersen reported bilateral lacrimation after unilat-
eral irritation of the nasal mucosa.41 Using capsaicin as a
stimulant and as a desensitizer, Philip and colleagues showed
that unilateral nasal challenge with capsaicin produced ocular
tearing and watering. This was reduced significantly after
repeated capsaicin challenges that led to desensitization of the
response.24
To determine whether nasal challenge with antigen
induces a nasal-ocular reflex, we performed a double-blind
crossover trial in 20 subjects with seasonal allergic rhinitis.42
We speculated that histamine, released by mast cells upon
allergen deposition on the nasal mucosa, initiated the afferent
limb of the reflex response which resulted in contralateral nasal
symptoms and also ocular symptoms within minutes of chal-
lenge. Therefore, we evaluated the effect of a topical antihista-
mine, azelastine, applied to the nasal cavity on the side of
challenge on both the nasal and ocular reflex responses. Subjects
were challenged with antigen in one nostril using filter paper
discs, and the response was monitored in both nostrils and in
both eyes. Symptoms were recorded. Discs (intranasally) and
Schirmer strips (intraocularly) were used for collecting secre-
tions in both nostrils and eyes and were weighed before and after
collection allowing us to calculate the weight of generated nasal
and ocular secretions, objective measures of rhinorrhea and
watery eyes, respectively. The discs and Schirmer strips were
then placed in buffer to allow elution of collected secretions and
the supernatants were measured for levels of histamine, an
indicator of mast cell activation, and albumin, a marker of
vascular permeability.
Subjects were treated once topically at the site of
challenge with azelastine or placebo. After placebo treatment,
ipsilateral nasal challenge caused nasal symptoms and an
increase in bilateral nasal secretion weights, both of which
were blocked by treatment with azelastine. Levels of hista-
mine and albumin increased only at the site of nasal challenge
and azelastine inhibited the increase in albumin, but not that
in histamine. These findings are not new and have been
demonstrated by our and other laboratories previously. They
cement the existence of a nasonasal reflex and the important
role of histamine in its generation. As far as the ocular
response, symptoms of itchy and watery eyes increased
significantly after allergen challenge, compared with sham
challenge, when the subjects were premedicated with placebo
(Fig. 1). This supports our hypothesis of the role of the
naso-ocular reflex in the generation of ocular symptoms after
allergen deposition on the nasal mucosa. Furthermore, the eye
symptoms were inhibited by premedication with azelastine also
suggesting that histamine, released by allergen challenge, was
important in the genesis of the ocular symptoms (Fig. 1). Ocular
secretion weights increased bilaterally after placebo and were
not inhibited by azelastine. Unfortunately, ocular secretion col-
lection was technically difficult and ocular secretion weights are
probably not as reliable an indicator of the ocular response as
eye symptoms. This is related to the fact that the Schirmer strips
led to irritation of the eyes and a high baseline of secretions even
after the sham nasal challenge. In summary, the above data
suggested that nasal allergen challenge induces histamine release
at the site of the challenge, which causes both a nasonasal and a
nasal ocular reflex. This antigen induced reflex is blocked by an
H1 receptor antagonist applied at the site of the challenge. These
observations support the hypothesis that eye symptoms associ-
ated with allergic rhinitis probably arise, at least in part, from a
nasal-ocular reflex.
To follow up on this study and investigate the effects of
intranasal steroids on the nasal-ocular reflex, we performed
double-blind, placebo-controlled, cross-over experiment in
20 subjects who had seasonal allergic rhinitis.43 We hypoth-
esized that repeated nasal allergen challenges would lead to
priming and augmentation of nasonasal and nasal-ocular
reflexes and that intranasal steroids would decrease inflam-
mation and subsequently inhibit both nasonasal and nasal-
ocular reflexes thus resulting in reduction of eye symptoms.
Nasal antigen challenge was performed consecutively for 3
days after 1 week of treatment with either placebo or fluti-
casone furoate nasal spray. Subjects recorded their nasal and
ocular symptoms, and nasal secretions were quantified. Nasal
scrapings for quantifying eosinophils were obtained before
each antigen challenge. When subjects were receiving pla-
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cebo, nasal challenge with antigen led to sneezing, a nasona-
sal and a nasal-ocular reflex. Priming in the number of
sneezes, contralateral nasal secretion weights, and total eye
symptoms were observed (Fig. 2). Pretreatment with flutica-
sone furoate nasal spray reduced sneezing, the nasonasal and
nasal-ocular reflexes, and the amount of eosinophils in nasal
secretions (Fig. 2). The results of this study helped confirm
the existence of a nasal-ocular reflex after allergen challenge
of the nose, and demonstrated the exaggeration, or priming,
of this reflex by repeated exposure to allergen and thus
supported the role of the nasal-ocular reflex in the genesis of
at least part of the eye symptoms in patients with AR. This
study also helped demonstrate the efficacy of an intranasal
steroid (fluticasone furoate) in reducing allergic inflamma-
tion, priming and subsequently the nasal-ocular reflex and
ocular symptoms. Our results therefore support a mechanism
that helps explain how control of eye symptoms can be
achieved by the administration of an intranasal steroid in
patients with seasonal allergic rhinitis.
CONCLUSION
Eye symptoms (itching, watery eyes, and redness) are
an important part of the overall burden of AR and are
associated with significant bother to allergy sufferers. These
effects probably occur by several mechanisms, the most
obvious of which, is the direct deposition of allergen in the
conjunctiva and the generation of an ocular inflammatory
response. Another mechanism that might contribute to the
genesis of ocular symptoms in allergic individuals is a neural
reflex generated in the nose upon exposure to allergen that
results in an amplification of the allergic response to the other
nostril and also to both eyes. This mechanism might explain
the efficacy of intranasally administered steroids in control-
ling ocular symptoms. In this article, we have reviewed
evidence obtained both from experimental challenges and
clinical studies that supports an important role for the nasal-
ocular reflex in the eye symptoms of AR and, at least
partially, explains the efficacy of intranasal steroids in con-
trolling these symptoms.
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